epha.health
Feedback
New Case
Register
busy
1
Drugs
|
0
Findings
|
Advice

Pharmacological advice for aldesleukin

plan
Print
Version 6.0.32 (Beta Preview)

Summary Summary info 72%

Pharmacokinetic 0%
Aldesleukin
Scores 0%
QT time prolongation
Anticholinergic effects
Serotonergic effects
Adverse drug events -28%
Diarrhea
Shivering
Vomiting

Variants ✨

For the computationally intensive evaluation of the variants, please choose the paid standard subscription.

medication Intended use

Aldesleukin is used to treat metastatic (spread) kidney cancer when the kidney has had to be removed. It is infused intravenously or subcutaneously as a solution. Aldesleukin is a genetically modified variant of human interleukin-2 (IL-2), also known as T-cell growth factor. As part of the so-called cellular immune system, T cells also attack cancer cells and destroy them. Like the natural IL-2, aldesleukin increases the activity of T cells and thus has a growth-inhibiting and killing effect on tumor tissue. The exact mechanism has not been conclusively clarified. Unwanted effects can include flu-like symptoms, low blood pressure, anxiety, changes in the blood count (e.g. leukopenia), reduced kidney and lung function, shortness of breath or fluid retention (edema).

undefined Pharmacokinetics info -0%

∑ Exposureaald
Aldesleukin 1
Symbol (a): x-fold change in AUC
Legend (n.a.): Information not available

Since only aldesleukin was entered without any further substances, no pharmacokinetic interactions can be detected.

Rating: The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability of aldesleukin is unknown. Protein binding [Pb] is not known. The metabolism does not take place via the common cytochromes.

transmitter Serotonergic effects info -0%

Scores ∑ Points ald
Serotonergic Effects a 0 Ø
Symbol (a): Increased risk from 5 points.

Rating: According to our knowledge, aldesleukin does not increase serotonergic activity.

transmitter Anticholinergic effects info -0%

Scores ∑ Points ald
Kiesel b 0Ø
Symbol (b): Increased risk from 3 points.

Rating: According to our findings, aldesleukin does not increase anticholinergic activity.

electrocardiogram QT time prolongation info -0%

We do not know of any QT-prolonging potential for aldesleukin.

Other side effects General adverse effects info -28%

Side effects ∑ frequency ald
Diarrhea67.0 %67.0
Shivering52.0 %52.0
Vomiting50.0 %50.0
Rash42.0 %42.0
Hyperbilirubinemia40.0 %40.0
Thrombocytopenia37.0 %37.0
Nausea35.0 %35.0
Dyspnea35.0 %35.0
Confusion34.0 %34.0
Elevated serum creatinine33.0 %33.0
Tabular extract of the most common side effects
Sign (+): side effect described, but frequency not known
Sign (↑/↓): frequency rather higher / lower due to exposure

Hematological
Anemia (29%): aldesleukin

Systemic
Fever (29%): aldesleukin
Malaise (27%): aldesleukin

Cardiac
Peripheral edema (28%): aldesleukin
Tachycardia (23%): aldesleukin
Myocardial infarction: aldesleukin
Hypotension: aldesleukin
Supraventricular tachycardia: aldesleukin

Dermatological
Pruritus (24%): aldesleukin

Neurological
Asthenia (23%): aldesleukin
Somnolence (22%): aldesleukin

Gastrointestinal
Loss of appetite (20%): aldesleukin

Vascular
Capillary leak syndrome: aldesleukin

Limitations Limitations

Based on your and scientific information, we assess the individual risk of undesirable side effects. The orange filled bars signal the basic potential of the drugs to cause this side effect. These recommendations are intended to advise professionals and are not a substitute for consultation with a doctor. In the restricted test version (alpha), the risk of all substances has not yet been conclusively assessed.

literature References

No literature information available.

epha.ch AG

Stadelhoferstrasse 40 8001 Zurich Switzerland
Github LinkedIn Facebook Twitter
kontakt@epha.ch

General

Imprint Data protection Terms of Use About us API

Languages

Deutsch English Français Italiano Español
Copyright © 2020 epha.ch - All rights reserved